How Long After Taking Valtrex Are You Contagious?

Valtrex (valacyclovir) reduces how contagious you are, but it does not flip a switch from contagious to not contagious on any particular day. Even after the drug reaches full effect in your bloodstream, herpes simplex virus can still shed from your skin or mucous membranes and potentially spread to a partner. The honest answer is that you remain somewhat contagious the entire time you carry the virus, whether or not you are taking Valtrex, though the medication cuts the risk substantially. How much it cuts the risk, and how timing matters, depends on whether you are treating an active outbreak or taking the drug daily as suppressive therapy.

How Quickly Valtrex Reaches the Virus

After you swallow a 1,000 mg dose of Valtrex, it converts to acyclovir in your body and hits peak blood levels within about one to two hours, with a half-life of roughly three hours.¹ That means the drug is working against the virus quickly, but “working” here means interfering with viral replication, not sterilizing the area. Acyclovir blocks the virus from making new copies of itself, so any virus already assembled and sitting on a skin surface is not destroyed by the drug. This distinction matters: Valtrex shortens how long active shedding lasts and lowers how much virus is present, but it does not instantly render you non-contagious from the moment you take it.

During an Active Outbreak

If you are taking Valtrex to treat a genital herpes outbreak, the drug shortens the episode by about a day on average. In a head-to-head trial comparing valacyclovir, acyclovir, and placebo, both antivirals resolved outbreaks in a median of about five days compared to roughly six days on placebo. Viral shedding stopped about two and a half times faster in people treated with valacyclovir than in those on placebo.² Faster, though, is relative. You should expect several days of active shedding during an outbreak even with treatment.

Researchers have used PCR testing, which is far more sensitive than traditional culture, to measure how long viral DNA remains detectable in genital lesions. In a small study that followed recurrent outbreaks closely, cultures turned negative after an average of about two and a half days, but PCR still detected herpes DNA for an average of nearly seven days per episode.³ Whether detectable DNA always means you can transmit the virus is debated, but it shows the virus hangs around longer than the visible sore. The practical takeaway: during an outbreak, assume you are contagious from the first tingle through complete healing of the skin, even if you started Valtrex right away.

Why Starting Early Makes a Real Difference

Timing your first dose matters more than many people realize. If you begin valacyclovir within six hours of the first symptom or tingling sensation, you roughly double your odds of aborting the outbreak entirely, meaning the lesion never fully forms.⁴ An aborted outbreak is the best-case scenario for contagiousness: if the lesion never develops, viral shedding is brief and minimal. Waiting until sores are fully established still helps speed healing and reduce pain, but you lose the window to prevent the outbreak from running most of its course. If you have episodic treatment on hand, keeping the pills accessible so you can take them at the very first sign of prodrome is one of the most effective things you can do.

Suppressive Therapy and the Shedding You Cannot Feel

The trickier question is not about outbreaks at all. Most herpes transmission happens when the infected person has no symptoms and does not know the virus is active on their skin. This is called asymptomatic or subclinical shedding, and it happens on roughly three percent of days in people with healthy immune systems when measured by culture, and more when measured by PCR.⁵ Because the majority of transmission events occur during these silent shedding episodes, daily suppressive Valtrex is primarily aimed at reducing this hidden risk.

Daily valacyclovir does a solid job at this. In one study of people who had HSV-2 but no history of recognized genital outbreaks, suppressive therapy reduced subclinical shedding by about 71 percent compared to placebo, dropping it from roughly five percent of days to one and a half percent.⁶ In people newly diagnosed with genital herpes, the reduction was even steeper: total shedding dropped by about 78 percent, from around 13.5 percent of days on placebo to about 2.9 percent on valacyclovir.⁷

Those are meaningful reductions, but they are not zero. Even on daily suppressive Valtrex, virus still surfaces on a small percentage of days. You can think of it this way: without the drug, herpes might be detectable on your skin roughly one out of every ten days; with daily Valtrex, that drops to roughly one out of every 30 or 40 days. You are contagious on significantly fewer days, but you cannot know which specific days those are.

What the Transmission Trial Found

The strongest evidence on whether Valtrex actually prevents passing herpes to a partner comes from a landmark randomized trial published in the New England Journal of Medicine. Researchers enrolled couples where one partner had genital HSV-2 and the other did not. The infected partner took either 500 mg of valacyclovir daily or placebo for eight months. Among partners of people taking Valtrex, about 1.9 percent acquired HSV-2 overall, compared to 3.6 percent in the placebo group, a roughly 48 percent reduction. When looking only at clinically symptomatic infections, the protection was even stronger: four cases in the Valtrex group versus 16 on placebo, a 75 percent reduction in symptomatic disease.⁸

Those numbers tell an important story. Daily Valtrex cuts transmission risk roughly in half, but the risk does not reach zero. In a given year, the per-partner transmission rate dropped from about four percent on placebo to about two percent on the drug.⁹ That residual two percent matters if you are trying to protect a partner, and it is why clinicians recommend combining Valtrex with condom use. In the same trial, couples who used condoms consistently had an even lower rate of transmission on top of the valacyclovir benefit.⁹ Neither measure alone eliminates the risk, but layering them brings it down substantially.

Short Shedding Bursts That Break Through

One finding that surprises many people is that even high-dose antiviral therapy does not prevent all shedding episodes. Researchers running crossover trials found that short bursts of viral reactivation, sometimes lasting less than 12 hours, still occur on suppressive Valtrex and even on higher-than-standard doses.¹⁰ These brief episodes release virus before the drug has time to shut down replication. Since the virus lives in nerve cells and periodically reactivates at the skin surface, no currently available antiviral can intercept every single reactivation event. The drug is most effective at cutting down longer, higher-quantity shedding episodes; the very short flickers of virus are harder to suppress.

This does not mean the drug is failing. It means the biology of herpes involves rapid, unpredictable bursts of viral activity that outpace even a constantly circulating antiviral. These short episodes likely carry a lower quantity of virus and may be less likely to result in transmission than longer shedding events, but they have not been fully characterized in terms of infectivity.

Cold Sores and Oral Herpes

Most of the major transmission trials focus on genital herpes caused by HSV-2, but many people searching about Valtrex and contagiousness are dealing with cold sores caused by HSV-1. The dynamics are broadly similar: Valtrex reduces how often and how much virus is present. In a study of people with recurrent cold sores, a short course of valacyclovir cut the median number of shedding days from four to about 1.8, and the proportion of days with detectable virus dropped from 40 percent to roughly 17.5 percent.¹¹ The total quantity of viral DNA detected was also significantly lower in the treated group.

For cold sores, most people take Valtrex episodically at the first sign of a sore rather than every day. You should consider yourself contagious from the moment you feel the tingling prodrome until the sore has completely crusted over and healed. Valtrex shortens this window but does not eliminate it overnight. Avoiding kissing or sharing utensils during an active cold sore remains important whether or not you are on the medication.

Who Stays Contagious Longer

Not everyone sheds the same amount of virus, and individual shedding rates affect how long you remain contagious during and between outbreaks. A few patterns stand out in the research.

People who were recently infected shed considerably more virus than those who have had herpes for years. In one study, subjects who were newly diagnosed but still HSV-2 seronegative, meaning they were in the earliest phase of infection before their immune system had mounted a full antibody response, had shedding rates four to five times higher than those who were newly diagnosed but already seropositive.⁷ If you have just been diagnosed, your contagiousness is likely higher than someone who has been managing the virus for a decade, and daily suppressive Valtrex becomes especially useful in this period.

People with weakened immune systems, such as organ transplant recipients or those living with HIV, tend to shed more frequently and may respond less predictably to standard antiviral doses. The general shedding and transmission data from the large trials were gathered in people with healthy immune systems, so if you are immunocompromised, the residual risk on Valtrex may be higher and the dosing regimen may be different. Your doctor will likely adjust accordingly.

Why You Cannot Pin Down an Exact Timeframe

The question “how long after taking Valtrex am I contagious” implies there is a finish line, a point after which the risk drops to zero. For herpes, that finish line does not exist. The virus establishes a lifelong infection in nerve cells and reactivates intermittently for life. Valtrex suppresses these reactivations but cannot eradicate the virus. Every study measuring shedding on suppressive therapy still finds some days with detectable virus. Even the most effective dosing schedules leave a residual risk.

That said, the risk profile changes over time in your favor. After a first episode of genital herpes, outbreaks tend to become less frequent and less severe over subsequent years. Subclinical shedding rates also tend to decline. Taking daily Valtrex accelerates this decline in effective contagiousness, and the combination of natural immune maturation and antiviral suppression means that someone who has been on suppressive therapy for several years likely poses a lower transmission risk than someone newly diagnosed and newly starting the drug.

Practical Steps to Minimize Transmission Risk

Since Valtrex alone does not make you non-contagious, managing transmission involves layering multiple strategies. The evidence supports combining approaches:

Daily suppressive Valtrex: Cuts transmission risk roughly in half and reduces shedding by 70 to 80 percent depending on the population studied.
Consistent condom use: Provides additional protection beyond what the drug achieves on its own. In the large transmission trial, couples who used condoms regularly on top of valacyclovir had even lower transmission rates.⁹
Avoiding sex during outbreaks: The quantity of virus present during a visible sore is far higher than during subclinical shedding. Abstaining from skin-to-skin contact in the affected area until complete healing is the single most effective step during an active episode.
Disclosure and communication: Giving a partner the information to make their own risk assessment is both an ethical standard and a practical one, since a partner who knows can watch for early symptoms and get tested if needed.

None of these measures is perfect alone, but combined they bring the annual risk of transmission down from the baseline of around four percent per year for discordant couples to something considerably lower. For many couples, that residual risk is manageable.

How Valtrex Compares to Other Antivirals

If you are wondering whether switching to a different antiviral would make you less contagious faster, the answer is probably not. In clinical trials, valacyclovir and acyclovir performed almost identically in terms of shortening outbreaks, reducing pain, and stopping viral shedding.² Valacyclovir’s main advantage is convenience: it is better absorbed and requires fewer pills per day than acyclovir, which makes people more likely to actually take it consistently.¹² Famciclovir is another option with similar efficacy. The differences between available antivirals are in dosing schedules and tolerability, not in how effectively they suppress shedding. No currently available antiviral will make you non-contagious. They all reduce the risk by a similar degree.

Antiviral Resistance and Breakthrough Shedding

A reasonable worry is whether the virus can become resistant to Valtrex, leaving you more contagious than expected. In practice, resistance is rare in people with healthy immune systems. Even in study participants who showed persistent shedding despite being on the drug, genetic sequencing of the virus did not find known resistance mutations.¹⁰ The breakthrough shedding appears to be a consequence of how fast the virus reactivates rather than the drug losing its effectiveness. In immunocompromised individuals, resistance is more of a concern and should be monitored by a physician, but for the vast majority of people taking Valtrex, the drug continues working as expected over years of use.

What PCR Detection Means for Real-World Contagiousness

Much of the modern shedding research uses PCR, which picks up tiny amounts of viral DNA that older culture methods would miss. This is useful for research, but it creates a question for everyday life: if PCR detects viral DNA on a given day, does that necessarily mean you could transmit the virus? Probably not always. Culture-based studies, which detect only virus capable of replicating, consistently find shedding on fewer days than PCR studies do.³ Some of the DNA picked up by PCR may represent viral fragments rather than intact, transmissible virus. This means the shedding percentages reported in PCR-based studies likely overestimate actual infectivity to some degree. But no one has nailed down exactly where the threshold lies between detectable DNA and real transmission risk, so erring on the side of caution remains the standard advice.

1
PubMed. Valaciclovir (BW256U87): the L-valyl ester of acyclovir
2
JAMA Dermatology. A Randomized, Placebo-Controlled Comparison of Oral Valacyclovir and Acyclovir in Immunocompetent Patients With Recurrent Genital Herpes Infections
3
PubMed. Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction
4
Sexually Transmitted Infections. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir
5
Oxford Academic. Herpes simplex virus: the importance of asymptomatic shedding
6
PubMed. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes
7
PubMed Central. Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes
8
PubMed. Once-daily valacyclovir to reduce the risk of transmission of genital herpes
9
PubMed Central. Reducing the transmission of genital herpes
10
PubMed Central. Ineffectiveness of daily standard and high-dose antiviral therapy in preventing short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials
11
Journal of the American Academy of Dermatology. Short-course valacyclovir for recurrent herpes labialis: a randomized, double-blind, placebo-controlled study
12
PubMed. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections